Histone deacetylases and cancer

By M A Glozak, E. Seto. Oncogene, 2007

1,192 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Histone Modifications and Cancer. (2016, background): “The contributions of specific HDAC subtypes to individual cancers are currently not fully understood (see Appendix B at the end of the article) (Barneda-Zahonero and Parra 2012).”
Histone Deacetylase Inhibitors: Potential in Cancer Therapy (2009, background): “1) [Bolden et al., 2006; Minucci and Pelicci, 2006; Glozak and Seto, 2007; Jones and Baylin, 2007; Rasheed et al., 2007; Xu et al., 2007; Dokmanovic et al., 2007a; Blackwell et al., 2008; Moradei et al., 2008; Shankar and Srivastava, 2008].”
New and emerging HDAC inhibitors for cancer treatment. (2014, neutral): “13) and key genes encoding DNA damage repair enzymes such as breast cancer 1, early onset ( BRCA1 ) and ataxia telangiectasia and Rad3 related ( ATR ) (14).”
HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention (2007, background): “Glozak and Seto (2007) summarize various links of these enzymes to cancer.”